MorphoSys will receive committed annual license fees, success-based development milestones, in addition to royalties on sales of marketed drug products emerging from the collaboration. MorphoSys chief scientific officer
IMA901 is a therapeutic cancer vaccine comprising 10 tumor-associated peptides (TUMAPs) that are frequently found to be over-expressed in the majority of patients suffering from renal cell carcinoma.
The new patent, entitled ‘Proteome-wide quantification of small molecule binding to cellular target proteins,’ (EP2045332B1) supports company’s chemical proteomics solutions for research and development. Cellular Target Profiling enables
The decision has been taken by DMC following a pre-specified interim analysis from the Phase II and III clinical trial. The partners said the trial did not meet
MycoTOOL test is a NAT-based detection system that is used for mycoplasma biosafety testing of approved biological products. Release testing with the MycoTOOL PCR-test from Roche Custom Biotech,
The technology works by sustaining high concentrations of drug in the gastrointestinal tract. The patent, which is titled ‘Pharmaceutical Compositions Comprising Drug and Concentration-Enhancing Polymers,’ complements a number
Brimonidine tartrate with timolol maleate ophthalmic solution is used for the reduction of elevated intraocular pressure. Hi-Tech plans to launch the product after the Company receives final approval
Anturol Gel, an oxybutynin gel incorporating Antares’ advanced transdermal delivery (ATD) Gel technology, is indicated for treatment in patients with overactive bladder (OAB). FDA is expected to complete
ViroXis has started a Phase II trial evaluating a drug substance derived from East Indian Sandalwood oil (EISO). The trial will be a double-blinded, placebo-controlled, dose range-finding trial
BBI608 is a first-in-class, cancer stem cell inhibitor, currently in clinical development. Through its undisclosed molecular target, BBI608 simultaneously inhibits multiple key cancer cell stemness pathways. BBI608 targets
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.